ClinicalTrials.gg
TerminatedNCT04514406APERTO CVSUpdated Feb 7, 2024

APERTO CVS PMCF Study

An observational study in Dialysis; Complications, Central Vein Obstruction and Stenosis, sponsored by Cardionovum GmbH. Terminated at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Cardionovum GmbH · Observational

How we know

Why this study was terminated
no enrolments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Constriction, Pathologic with a site in Germany — 6 open to participants now, 8 under way, none of them phase 3. Constriction, Pathologic · Germany.

Enrollment
20th of 20
6 · median 122
Started
2021
with 5 others
Observational
20 of 43
5 open now
Registered
29th of 43
by date

Among the 43 studies in Constriction, Pathologic with a site in Germany, this one is the 20th largest by enrollment of the 20 observational ones that give a count, is one of 6 that started in 2021, is one of 20 observational ones, and was the 29th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

6 of the 43 studies in Constriction, Pathologic with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Constriction, Pathologic with a site in Germany, or all of them as a file.
02

Study summary

Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients

Read the detailed description

The APERTO CVS PMCF study is aimed to evaluate safety and effectiveness of treatment of central veins (re)stenosis in dialysis patients at short and mid-term follow up, after treatment with APERTO OTW DCB. Primary endpoint will consist in evaluating the intervention free period for patients treated with APERTO OTW.

APERTO CVS PMCF Study will also collect data for post-market clinical follow up (PMCF) in a CE mark device used according to intended use

03

Conditions studied

  • Dialysis; Complications
  • Central Vein Obstruction
  • Stenosis
  • Restenosis

Keywords

  • Drug Coated Balloon
  • Central Veins Stenosis
  • Percutaneous Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Dialysis patients with symptoms for stenosis or restenosis of central veins to be treated with percutaneous angioplasty.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age >18, no pregnant women, able to perform fup visits, > 12 months
  • Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic stenosis (de novo or restenosis) of the central veins with significant (>50%) stenosis and diameter
  • The target lesion consists of one or more lesions with a target lesion length of less than or equal to 100 mm
  • The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in angiographic or ultrasound evaluation);
  • If there are other non-target lesions, then non-target lesions must be successfully cured with a not drug coated balloon before treating the target lesion;

Exclusion criteria

Exclusion Criteria:

  • Patients with CVS observed and estimated as nonsignificant (\< 50% stenosis) or a vessel > 12 mm in diameter by visual estimation;
  • the patient is now participating in another clinical trial to evaluate drug or medical device;
  • patient enrolled for this trial before;
  • prenatal pregnancy test result for women of is non-negative, Lactating woman;
  • patients, who underwent major surgical procedures (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study;
  • patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within 30 days after enrolment;
  • central veins lesions have been already treated with DCB before
  • presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in central veins
  • patients allergic or intolerant to paclitaxel, or contrast media;
  • patients whose is less than 1 year
  • presence of Thrombus in central veins
  • tumor compression
  • thoracic inlet syndrome
  • patients implanted with pacing or cardioverter devices with leads
  • any other central line within the target lesion
  • Patients with any as mentioned in the Instructions for Use (IFU) of the Device
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6 participants (actual)
Patient registry
No

Groups and cohorts

  • APERTO OTW DCB

    Dialysis patients treated with APERTO OTW following (re)stenosis of central veins

    Device: APERTO OTW DCB

Interventions

  • DeviceAPERTO OTW DCB

    Drug Coated Balloon Angioplasty

06

What researchers measure

Primary outcomes

  1. Clinically Assessed Intervention free period at 6 months fup

    clinically assessed intervention free period at 6 months (IFP) defined as dialysis access circuit with no need for clinically driven target lesion repeat intervention for symptom recurrence

    Time frame: 6 months

Secondary outcomes

  1. Procedural Technical Success

    Residual stenosis is no more than 30% after treatment with APERTO OTW measured by angiography

    Time frame: intraoperative

  2. Procedural Clinical Success

    After the procedure, haemodialysis access function improved, dialysis function restored, and at least one dialysis session completed

    Time frame: intraoperative

  3. Procedural Surgical Success

    On the basis of technical success, no major adverse events (MAE) occurred during hospitalization or treatment

    Time frame: intraoperative

  4. Major Adverse Event

    include death, stroke, thrombosis, allergic reactions, and pulmonary diseases (including pulmonary edema), bleeding complication with the need of transfusion

    Time frame: 12 months follow up

  5. Fistula Flow

    Flow measured with Echo Doppler measured at 6 months

    Time frame: 6 months

  6. Recirculation Rate

    Recirculation rate measured at 6 months

    Time frame: 6 months

07

Study locations

2 sites
  • Vivantes Klinikum
    Berlin, 10249, Germany
  • St.Franziskus Hospital
    Münster, 48145, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 17, 2020
StartActual
Jan 25, 2021
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04514406
Lead sponsor
Cardionovum GmbH
Collaborators
CliPS Service, OPIS srl
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Jan 25, 2021
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Last update
Feb 7, 2024

Study contacts

Petra Michel, MD
principal investigator · Klinikum Hochsauerland
Michael Lichtenberg, MD, FESC
study director · Klinikum Hochsauerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion